YiChang HEC ChangJiang Pharmaceutical Full Year 2023 Earnings: Beats Expectations

Simply Wall St

April 29, 2024

YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Full Year 2023 Results

Key Financial Results

Revenue: CN¥6.29b (up 68% from FY 2022).
Net income: CN¥1.99b (up by CN¥1.92b from FY 2022).
Profit margin: 32% (up from 2.0% in FY 2022). The increase in margin was driven by higher revenue.
EPS: CN¥2.26 (up from CN¥0.087 in FY 2022).

revenue-and-expenses-breakdown — SEHK:1558 Revenue and Expenses Breakdown April 29th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

YiChang HEC ChangJiang Pharmaceutical Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 2.3%. Earnings per share (EPS) also surpassed analyst estimates by 27%.

In the last 12 months, the only revenue segment was Sales of Pharmaceutical Products contributing CN¥6.29b. The largest operating expense was Sales & Marketing costs, amounting to CN¥1.55b (52% of total expenses). Explore how 1558's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 2.2% p.a. on average during the next 3 years, compared to a 9.9% growth forecast for the Pharmaceuticals industry in Hong Kong.

Performance of the Hong Kong Pharmaceuticals industry.

The company's shares are up 3.6% from a week ago.

Risk Analysis

What about risks? Every company has them, and we've spotted 1 warning sign for YiChang HEC ChangJiang Pharmaceutical you should know about.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.